Literature DB >> 33643288

Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

Jacob J E Koopman1,2, Mieke F van Essen2, Helmut G Rennke3, Aiko P J de Vries2, Cees van Kooten2.   

Abstract

The membrane attack complex-also known as C5b-9-is the end-product of the classical, lectin, and alternative complement pathways. It is thought to play an important role in the pathogenesis of various kidney diseases by causing cellular injury and tissue inflammation, resulting in sclerosis and fibrosis. These deleterious effects are, consequently, targeted in the development of novel therapies that inhibit the formation of C5b-9, such as eculizumab. To clarify how C5b-9 contributes to kidney disease and to predict which patients benefit from such therapy, knowledge on deposition of C5b-9 in the kidney is essential. Because immunohistochemical staining of C5b-9 has not been routinely conducted and never been compared across studies, we provide a review of studies on deposition of C5b-9 in healthy and diseased human kidneys. We describe techniques to stain deposits and compare the occurrence of deposits in healthy kidneys and in a wide spectrum of kidney diseases, including hypertensive nephropathy, diabetic nephropathy, membranous nephropathy, IgA nephropathy, lupus nephritis, C3 glomerulopathy, and thrombotic microangiopathies such as the atypical hemolytic uremic syndrome, vasculitis, interstitial nephritis, acute tubular necrosis, kidney tumors, and rejection of kidney transplants. We summarize how these deposits are related with other histological lesions and clinical characteristics. We evaluate the prognostic relevance of these deposits in the light of possible treatment with complement inhibitors.
Copyright © 2021 Koopman, van Essen, Rennke, de Vries and van Kooten.

Entities:  

Keywords:  C5b-9 (membrane attack complex [MAC]); biopsy; clinicopathological correlation; glomerular disease; histopathology; immunofluorescence; immunohistochemistry; renal

Mesh:

Substances:

Year:  2021        PMID: 33643288      PMCID: PMC7906018          DOI: 10.3389/fimmu.2020.599974

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  225 in total

1.  Detection of polymorphonuclear cells, superoxide dismutase and poly C9 in glomeruli of patients with IgA nephropathy.

Authors:  H C Chen; Y Tomino; Y Yaguchi; M Fukui; H Koide
Journal:  Nephron       Date:  1991       Impact factor: 2.847

2.  Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bit of both?

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  Kidney Int       Date:  2019-07       Impact factor: 10.612

3.  Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement.

Authors:  F Hugo; D Jenne; S Bhakdi
Journal:  Biosci Rep       Date:  1985-08       Impact factor: 3.840

4.  Membranoproliferative pattern of glomerular injury associated with complement component 9 deficiency due to Arg95Stop mutation.

Authors:  Takayoshi Miura; Shin Goto; Seitaro Iguchi; Hisaki Shimada; Mitsuhiro Ueno; Shin-ichi Nishi; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2010-11-06       Impact factor: 2.801

5.  Eculizumab treatment for rescue of renal function in IgA nephropathy.

Authors:  Therese Rosenblad; Johan Rebetz; Martin Johansson; Zivile Békássy; Lisa Sartz; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2014-06-13       Impact factor: 3.714

6.  Complement activation in early protocol kidney graft biopsies after living-donor transplantation.

Authors:  Ståle Sund; Torstein Hovig; Anna Varberg Reisaeter; Helge Scott; Øystein Bentdal; Tom Eirik Mollnes
Journal:  Transplantation       Date:  2003-04-27       Impact factor: 4.939

7.  Complement activation and effect of eculizumab in scleroderma renal crisis.

Authors:  Arnaud Devresse; Selda Aydin; Moglie Le Quintrec; Nathalie Demoulin; Patrick Stordeur; Catherine Lambert; Sara Gastoldi; Yves Pirson; Michel Jadoul; Johann Morelle
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

8.  Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis.

Authors:  Hannah R Wilson; Nicholas R Medjeral-Thomas; Alyssa C Gilmore; Pritesh Trivedi; Kathleen Seyb; Ramin Farzaneh-Far; Iva Gunnarsson; Agneta Zickert; Thomas D Cairns; Liz Lightstone; H Terence Cook; Matthew C Pickering
Journal:  Kidney Int       Date:  2019-01-14       Impact factor: 10.612

9.  PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma.

Authors:  Giuseppe Stefano Netti; Giuseppe Lucarelli; Federica Spadaccino; Giuseppe Castellano; Margherita Gigante; Chiara Divella; Maria Teresa Rocchetti; Federica Rascio; Vito Mancini; Giovanni Stallone; Giuseppe Carrieri; Loreto Gesualdo; Michele Battaglia; Elena Ranieri
Journal:  Aging (Albany NY)       Date:  2020-04-28       Impact factor: 5.682

10.  Complement Activation in Patients With Diabetic Nephropathy.

Authors:  Pascal Bus; Jamie S Chua; Céline Q F Klessens; Malu Zandbergen; Ron Wolterbeek; Cees van Kooten; Leendert A Trouw; Jan A Bruijn; Hans J Baelde
Journal:  Kidney Int Rep       Date:  2017-10-16
View more
  10 in total

Review 1.  Autoimmune-mediated renal disease and hypertension.

Authors:  Erika I Boesen; Rahul M Kakalij
Journal:  Clin Sci (Lond)       Date:  2021-09-17       Impact factor: 6.876

2.  Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models.

Authors:  Sarah M Carpanini; Megan Torvell; Ryan J Bevan; Robert A J Byrne; Nikoleta Daskoulidou; Takashi Saito; Takaomi C Saido; Philip R Taylor; Timothy R Hughes; Wioleta M Zelek; B Paul Morgan
Journal:  Acta Neuropathol Commun       Date:  2022-07-06       Impact factor: 7.578

3.  Complement Deposition Predicts Worsening Kidney Function and Underlines the Clinical Significance of the 2010 Renal Pathology Society Classification of Diabetic Nephropathy.

Authors:  Shimin Jiang; Dingxin Di; Yuanyuan Jiao; Guming Zou; Hongmei Gao; Wenge Li
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

Review 4.  Second and Third Generational Advances in Therapies of the Immune-Mediated Kidney Diseases in Children and Adolescents.

Authors:  Ryszard Grenda; Łukasz Obrycki
Journal:  Children (Basel)       Date:  2022-04-11

5.  Proteinuria is accompanied by intratubular complement activation and apical membrane deposition of C3dg and C5b-9 in kidney transplant recipients.

Authors:  Gustaf L Isaksson; Marie B Nielsen; Gitte R Hinrichs; Nicoline V Krogstrup; Rikke Zachar; Heidi Stubmark; Per Svenningsen; Kirsten Madsen; Claus Bistrup; Bente Jespersen; Henrik Birn; Yaseelan Palarasah; Boye L Jensen
Journal:  Am J Physiol Renal Physiol       Date:  2021-12-20

6.  Urinary C5b-9 as a Prognostic Marker in IgA Nephropathy.

Authors:  Byung Chul Yu; Jin Hoon Park; Kyung Ho Lee; Young Seung Oh; Soo Jeong Choi; Jin Kuk Kim; Moo Yong Park
Journal:  J Clin Med       Date:  2022-02-03       Impact factor: 4.241

Review 7.  The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?

Authors:  Felix Poppelaars; Bernardo Faria; Wilhelm Schwaeble; Mohamed R Daha
Journal:  J Clin Med       Date:  2021-10-14       Impact factor: 4.241

8.  Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.

Authors:  Gesa Tiller; Rosa G M Lammerts; Jessy J Karijosemito; Firas F Alkaff; Arjan Diepstra; Robert A Pol; Anita H Meter-Arkema; Marc A Seelen; Marius C van den Heuvel; Bouke G Hepkema; Mohamed R Daha; Jacob van den Born; Stefan P Berger
Journal:  Front Immunol       Date:  2022-04-13       Impact factor: 8.786

9.  Application of C5 inhibitors in glomerular diseases in 2021.

Authors:  Alexis Werion; Eric Rondeau
Journal:  Kidney Res Clin Pract       Date:  2022-03-15

10.  Complement activation in Hidradenitis suppurativa: Covert low-grade inflammation or innocent bystander?

Authors:  K R van Straalen; K Dudink; P Aarts; H H van der Zee; T P P van den Bosch; J Giang; E P Prens; J Damman
Journal:  Front Immunol       Date:  2022-09-21       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.